Samuel Waxman is a partner in the Emerging Growth Company and Mergers and Acquisitions practices at Paul Hastings. He is based in the firm's New York office.
Mr. Waxman's represents emerging to mature life sciences and technology companies is all aspects of their business and legal affairs, including company formation, equity financings, strategic alliances, IPOs and M&A transactions. Mr. Waxman also regularly represents venture capital and growth equity investment funds.
Accolades and Recognitions
Recognized as a leading M&A, technology and intellectual property lawyer in the Financial Times Innovative Lawyers Report, The Legal 500 and Chambers.
Intellectual Asset Management's Patent 1000: The World's Leading Patent Practitioners stated, "The 'street-smart' lawyer has made the most of an outstanding transactional platform at the firm and proved his mettle on some of the biggest acquisitions/divestitures around."
Named to the top "40 Under 40 M&A Professionals" in M&A Advisor (2012)
University of Virginia School of Law, J.D., 2000
University of Virginia, B.A. (with Distinction), 1997
Moderator, "The Future of Venture Capital", New York Venture Summit, July 2018
Smarter, Faster, Stronger: A New Suite of VC Model Docs, Law360, May 2018
NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital, Lexology, Nov 2017
Plenary Session Moderator, "In Pursuit of Growth, Savings, and Return on Investment: Pharma's Quest for Innovation Partnerships", Life Sciences Summit, November 2017
Guest Lecturer, "Life Sciences Patent Law", NYU School of Law, April 2017
Resigning From a Board of Directors: Considerations for VC Fund Designees, Lexology, March 2017
Panelist, Houlihan Lokey 2017 Illiquid Financial Assets Conference, March 2017
Venture Debt: An Attractive Tool for Start-up Companies, Law360, February 2017
Making the Grade: Negotiating IP Licenses with Academic Institutions, Licensing Journal, January 2017, Vol. 37 Issue 1
Panelist, "Dealmaking 2017: Exploring Academic-Industry Partnerships", New York Pharma Forum, January 2017
Revisiting the CVR: The Litigation Crucible, Lexology, November 2016
When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling Shareholders, Law360, July 2016
Legal Health Isn't Easy for Digital Health Companies, TechCrunch. April 2016.
Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller, Lexology, February 2016
Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR, The M&A Lawyer, January 2016.
Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things, Lexology, April 2015.
The Acquisition of IP Assets in Bankruptcy, Intellectual Property Magazine, July/August 2014.
Strategic Alliances and M&A
Deerfield Management, in connection with its early-stage therapeutic research partnerships with various elite academic institutions including The Broad Institute of MIT and Harvard, Johns Hopkins University, Harvard University, and the Dana Farber Cancer Institute.
Merck & Co. in connection with various M&A and strategic alliance transactions, most recently in connection with its strategic alliances with Amathus Therapeutics and Yumanity Therapeutics.
Elanco U.S., Inc., a subsidiary of Eli Lilly and Company, in its acquisition of Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccines portfolio.
Sony Corporation in connection with various M&A transactions.
Venture Capital & Emerging Growth Companies
Deerfield Management, in connection with various debt and minority equity investments.
Digitalis Ventures, as outside general counsel to human and companion animal health-focused venture fund.
Ascent Biomedical Ventures, in connection with various debt and minority equity investments.
Orchestra BioMed, as outside general counsel to medical device development and licensing company.
BlackIvy Group, in connection with various debt and minority equity investments.
Canopy Growth Corporation, in connection with various M&A transactions, including its agreement to acquire Acreage Holdings.
The Scotts Miracle-GroCompany, in connection with its minority investment in RIV Capital.
RIV Capital, in connection with various debt and minority equity investments.
Turning Point Brands, in connection with various debt and minority equity investments.
Tuatara Capital, in connection with various debt and minority equity investments.